CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis

Background and Objectives In multiple sclerosis (MS), peripheral immune cells use various cell trafficking molecules to infiltrate the CNS where they cause damage.The objective of this study was to investigate the involvement of coxsackie and adenovirus receptor–like membrane protein (CLMP) in the migration of immune cells into the CNS of patients with MS. Methods Expression of CLMP was measured in primary cultures of human brain endothelial cells (HBECs) and human meningeal endothelial cells (HMECs), postmortem brain samples, and peripheral blood mononuclear cells (PBMCs) from patients with MS and controls by RNA sequencing, quantitative PCR, immunohistochemistry, and flow cytometry. In vitro migration assays using HBECs and HMECs were performed to evaluate the function of CLMP. Results Using bulk RNA sequencing of primary cultures of human brain and meningeal endothelial cells (ECs), we have identified CLMP as a new potential cell trafficking molecule upregulated in inflammatory conditions. We first confirmed the upregulation of CLMP at the protein level on TNFα-activated and IFNγ-activated primary cultures of human brain and meningeal ECs. In autopsy brain specimens from patients with MS, we demonstrated an overexpression of endothelial CLMP in active MS lesions when compared with normal control brain tissue. Flow cytometry of human PBMCs demonstrated an increased frequency of CLMP+ B lymphocytes and monocytes in patients with MS, when compared with that in healthy controls. The use of a blocking antibody against CLMP reduced the migration of immune cells across the human brain and meningeal ECs in vitro. Finally, we found CLMP+ immune cell infiltrates in the perivascular area of parenchymal lesions and in the meninges of patients with MS. Discussion Collectively, our data demonstrate that CLMP is an adhesion molecule used by immune cells to access the CNS during neuroinflammatory disorders such as MS. CLMP could represent a target for a new treatment of neuroinflammatory conditions.

[1]  F. Quintana,et al.  DICAM promotes TH17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation , 2022, Science Translational Medicine.

[2]  A. Rae-Grant,et al.  Diagnosis and Treatment of Multiple Sclerosis: A Review. , 2021, JAMA.

[3]  F. Rathjen.  The CAR group of Ig cell adhesion proteins–Regulators of gap junctions? , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.

[4]  A. Bar-Or,et al.  Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers , 2019, Science Translational Medicine.

[5]  P. Duquette,et al.  CD70 defines a subset of proinflammatory and CNS-pathogenic TH1/TH17 lymphocytes and is overexpressed in multiple sclerosis , 2019, Cellular & Molecular Immunology.

[6]  F. Rathjen,et al.  Cell-cell communication mediated by the CAR subgroup of immunoglobulin cell adhesion molecules in health and disease , 2017, Molecular and Cellular Neuroscience.

[7]  B. Engelhardt,et al.  The movers and shapers in immune privilege of the CNS , 2017, Nature Immunology.

[8]  F. Zipp,et al.  Dendritic cells as therapeutic targets in neuroinflammation , 2016, Cellular and Molecular Life Sciences.

[9]  D. Pleasure,et al.  Therapeutic depletion of monocyte-derived cells protects from long-term axonal loss in experimental autoimmune encephalomyelitis , 2016, Journal of Neuroimmunology.

[10]  C. Larochelle,et al.  JAML mediates monocyte and CD8 T cell migration across the brain endothelium , 2015, Annals of clinical and translational neurology.

[11]  T. Yednock,et al.  Melanoma cell adhesion molecule–positive CD8 T lymphocytes mediate central nervous system inflammation , 2015, Annals of neurology.

[12]  H. Wiendl,et al.  VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells , 2014, Journal of Neuroimmunology.

[13]  A. Nusrat,et al.  JAM-related proteins in mucosal homeostasis and inflammation , 2014, Seminars in Immunopathology.

[14]  D. Centonze,et al.  Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration , 2014, Multiple sclerosis.

[15]  A. Nusrat,et al.  JAM-related proteins in mucosal homeostasis and inflammation , 2014, Seminars in Immunopathology.

[16]  T. Yednock,et al.  Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. , 2012, Brain : a journal of neurology.

[17]  F. Charron,et al.  The Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence , 2011, Science.

[18]  C. Larochelle,et al.  How do immune cells overcome the blood–brain barrier in multiple sclerosis? , 2011, FEBS letters.

[19]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[20]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[21]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[22]  P. Duquette,et al.  Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosis , 2009, Annals of neurology.

[23]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[24]  P. Couraud,et al.  JAM-L–mediated leukocyte adhesion to endothelial cells is regulated in cis by α4β1 integrin activation , 2008, The Journal of cell biology.

[25]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[26]  A. Prat,et al.  The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. , 2008, Brain : a journal of neurology.

[27]  Danica Stanimirovic,et al.  Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system , 2008, Nature Immunology.

[28]  S. Cepok,et al.  Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.

[29]  R. Alon,et al.  Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.

[30]  P. Meda,et al.  Dual interaction of JAM-C with JAM-B and alpha(M)beta2 integrin: function in junctional complexes and leukocyte adhesion. , 2005, Molecular biology of the cell.

[31]  H. Makino,et al.  Identification of adipocyte adhesion molecule (ACAM), a novel CTX gene family, implicated in adipocyte maturation and development of obesity. , 2005, The Biochemical journal.

[32]  J. Fuxe,et al.  CLMP, a Novel Member of the CTX Family and a New Component of Epithelial Tight Junctions* , 2004, Journal of Biological Chemistry.

[33]  K. Preissner,et al.  The Junctional Adhesion Molecule 3 (JAM-3) on Human Platelets is a Counterreceptor for the Leukocyte Integrin Mac-1 , 2002, The Journal of experimental medicine.

[34]  S. Cunningham,et al.  JAM2 interacts with alpha4beta1. Facilitation by JAM3. , 2002, The Journal of biological chemistry.

[35]  A. Zernecke,et al.  JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes , 2002, Nature Immunology.

[36]  E. Dejana,et al.  Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration , 1998, The Journal of cell biology.

[37]  Y. Yamori,et al.  ASTROCYTE‐CONDITIONED MEDIUM INDUCES BLOOD‐BRAIN BARRIER PROPERTIES IN ENDOTHELIAL CELLS , 1997, Clinical and experimental pharmacology & physiology.

[38]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[39]  B. Engelhardt,et al.  Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. , 1994, The American journal of pathology.

[40]  C. Brosnan,et al.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.

[41]  Hans Lassmann,et al.  An updated histological classification system for multiple sclerosis lesions , 2016, Acta Neuropathologica.

[42]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[43]  K. Zen,et al.  Neutrophil migration across tight junctions is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils. , 2005, Molecular biology of the cell.